Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel Gusenleitner

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
BMC Bioinformatics|February 5, 2011
GCOD - GeneChip Oncology DatabaseFenglong Liu, Joseph A White, Corina Antonescu, et al.
Bioinformatics (Oxford, England)|July 14, 2012
iBBiG: iterative binary bi-clustering of gene setsDaniel Gusenleitner, Eleanor A Howe, Stefan Bentink, et al.
Bioinformatics (Oxford, England)|January 9, 2013
RamiGO: an R/Bioconductor package providing an AmiGO visualize interfaceMarkus S Schröder, Daniel Gusenleitner, John Quackenbush, et al.
Plos One|July 25, 2014
Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of actionDaniel Gusenleitner, Scott S Auerbach, Tisha Melia, et al.
Bioinformatics (Oxford, England)|January 25, 2015
ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathwaysYing Shen, Mumtahena Rahman, Stephen R Piccolo, et al.
Journal for Immunotherapy of Cancer|March 8, 2018
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patientsPriyanka B Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, et al.
Molecular Pharmacology|August 31, 2016
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer CellsOlga Novikov, Zhongyan Wang, Elizabeth A Stanford, et al.
Journal for Immunotherapy of Cancer|June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Blood Advances|January 4, 2018
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunitiesElizabeth A Morgan, M Patrick Sweeney, Tamiwe Tomoka, et al.
Blood|September 13, 2017
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaChristopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
BMC Bioinformatics|February 5, 2011
GCOD - GeneChip Oncology DatabaseFenglong Liu, Joseph A White, Corina Antonescu, et al.
Bioinformatics (Oxford, England)|July 14, 2012
iBBiG: iterative binary bi-clustering of gene setsDaniel Gusenleitner, Eleanor A Howe, Stefan Bentink, et al.
Bioinformatics (Oxford, England)|January 9, 2013
RamiGO: an R/Bioconductor package providing an AmiGO visualize interfaceMarkus S Schröder, Daniel Gusenleitner, John Quackenbush, et al.
Plos One|July 25, 2014
Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of actionDaniel Gusenleitner, Scott S Auerbach, Tisha Melia, et al.
Bioinformatics (Oxford, England)|January 25, 2015
ASSIGN: context-specific genomic profiling of multiple heterogeneous biological pathwaysYing Shen, Mumtahena Rahman, Stephen R Piccolo, et al.
Journal for Immunotherapy of Cancer|March 8, 2018
Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patientsPriyanka B Subrahmanyam, Zhiwan Dong, Daniel Gusenleitner, et al.
Molecular Pharmacology|August 31, 2016
An Aryl Hydrocarbon Receptor-Mediated Amplification Loop That Enforces Cell Migration in ER-/PR-/Her2- Human Breast Cancer CellsOlga Novikov, Zhongyan Wang, Elizabeth A Stanford, et al.
Journal for Immunotherapy of Cancer|June 21, 2022
Spartalizumab or placebo in combination with dabrafenib and trametinib in patients with <i>BRAF</i> V600-mutant melanoma: exploratory biomarker analyses from a randomized phase 3 trial (COMBI-i)Hussein A Tawbi, Caroline Robert, Jan C Brase, et al.
Blood Advances|January 4, 2018
Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunitiesElizabeth A Morgan, M Patrick Sweeney, Tamiwe Tomoka, et al.
Blood|September 13, 2017
Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphomaChristopher D Carey, Daniel Gusenleitner, Mikel Lipschitz, et al.
Pageof 3